Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Objective Neuronal damage is the morphological substrate of persisting neurological disability. Neurofilaments (Nf) are cytoskeletal proteins of neurons and their release into cerebrospinal fluid has shown encouraging results as a biomarker for neurodegeneration. This study aimed to validate the quantification of the Nf light chain (NfL) in blood samples, as a biofluid source easily accessible for longitudinal studies. Methods We developed and applied a highly sensitive electrochemiluminescence (ECL) based immunoassay for quantification of NfL in blood and CSF. Results Patients with Alzheimer’s disease (AD) (30.8 pg/ml, n=20), Guillain-Barré-syndrome (GBS) (79.4 pg/ml, n=19) or amyotrophic lateral sclerosis (ALS) (95.4 pg/ml, n=46) had higher serum NfL values than a control group of neurological patients without evidence of structural CNS damage (control patients, CP) (4.4 pg/ml, n=68, p<0.0001 for each comparison, p=0.002 for AD patients) and healthy controls (HC) (3.3 pg/ml, n=67, p<0.0001). Similar differences were seen in corresponding CSF samples. CSF and serum levels correlated in AD (r=0.48, p=0.033), GBS (r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001), but not in CP (r=0.11, p=0.3739). The sensitivity and specificity of serum NfL for separating ALS from healthy controls was 91.3% and 91.0%. Conclusions We developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum (NfLUmea47:3); levels in ALS were more than 20-fold higher than in controls. Our data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.

[1]  J. Schiefer,et al.  Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest. , 2013, International journal of cardiology.

[2]  M. Reilly,et al.  Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain‐Barré syndrome , 2013, Muscle & nerve.

[3]  C. Enzinger,et al.  CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome , 2013, Multiple sclerosis.

[4]  L. Kappos,et al.  A comparative study of CSF neurofilament light and heavy chain protein in MS , 2013, Multiple sclerosis.

[5]  G. Plant,et al.  The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies , 2012, Multiple sclerosis international.

[6]  K. Blennow,et al.  The Neuropathology and Neurobiology of Traumatic Brain Injury , 2012, Neuron.

[7]  Gerry Shaw,et al.  Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  J. Tsao.  Comment on “Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model” , 2012, Science Translational Medicine.

[9]  Robin O Cleveland,et al.  Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model , 2012, Science Translational Medicine.

[10]  B. Romner,et al.  Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest , 2012, Critical Care.

[11]  J. Glass,et al.  Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS , 2012, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[12]  M. Brown,et al.  Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign , 2011, Neurochemical Research.

[13]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[14]  P. Mccombe,et al.  Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke , 2011, Journal of the Neurological Sciences.

[15]  C. Shaw,et al.  Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS , 2011, Journal of neurochemistry.

[16]  L. Kappos,et al.  Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis , 2011, Neurology.

[17]  Axel Petzold,et al.  A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect , 2011, Journal of Neuroscience Methods.

[18]  A. Minagar.  Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab , 2011 .

[19]  M. Filippi,et al.  Evidence for acute neurotoxicity after chemotherapy , 2010, Annals of neurology.

[20]  L. Kappos,et al.  A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein , 2010, Journal of Neuroimmunology.

[21]  G. Giovannoni.  Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’ , 2010, Multiple sclerosis.

[22]  Gerry Shaw,et al.  Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF‐H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF‐H as a potential ALS biomarker , 2009, Journal of neurochemistry.

[23]  Y. Itoyama,et al.  CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain‐Barré syndrome , 2009, Muscle & nerve.

[24]  B. Hemmer,et al.  EFNS guidelines on disease‐specific CSF investigations , 2009, European journal of neurology.

[25]  F. Bouwman,et al.  Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis , 2009, Neurology.

[26]  G. Shaw,et al.  Detection of Phosphorylated NF-H in the Cerebrospinal Fluid and Blood of Aneurysmal Subarachnoid Hemorrhage Patients , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  K. Blennow,et al.  Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype , 2007, European journal of neurology.

[28]  M N Rossor,et al.  A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia , 2007, Neurodegenerative Diseases.

[29]  M. Reilly,et al.  CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndrome , 2006, Neurology.

[30]  D. Schöttle,et al.  The Neurofilament Heavy Chain (NfHSMI35) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[31]  H. Tumani,et al.  Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis , 2006, Multiple sclerosis.

[32]  A. Ludolph,et al.  Axonal damage markers in cerebrospinal fluid are increased in ALS , 2006, Neurology.

[33]  Gerry Shaw,et al.  Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. , 2005, Biochemical and biophysical research communications.

[34]  N. Norgren,et al.  Cerebrospinal fluid levels of neurofilament light in chronic experimental autoimmune encephalomyelitis , 2005, Brain Research Bulletin.

[35]  A. Petzold.  Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss , 2005, Journal of the Neurological Sciences.

[36]  N. Norgren,et al.  Neurofilament and glial fibrillary acidic protein in multiple sclerosis , 2004, Neurology.

[37]  G. Plant,et al.  Axonal degeneration and inflammation in acute optic neuritis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[38]  M. Clanet,et al.  Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis , 2004, Multiple sclerosis.

[39]  N. Norgren,et al.  Elevated neurofilament levels in neurological diseases , 2003, Brain Research.

[40]  G. Giovannoni,et al.  A specific ELISA for measuring neurofilament heavy chain phosphoforms. , 2003, Journal of immunological methods.

[41]  N. Norgren,et al.  Monoclonal antibodies selective for low molecular weight neurofilaments. , 2002, Hybridoma and hybridomics.

[42]  R. Barohn,et al.  Toward earlier diagnosis of amyotrophic lateral sclerosis , 1998, Neurology.

[43]  C. Wikkelsø,et al.  Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.

[44]  M Haupt,et al.  [Clinical diagnosis of Alzheimer's disease]. , 1988, Deutsche medizinische Wochenschrift.